Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of TOF-Watch SX T4/T1 ratio with manual T4 reappearance after sugammadex reversal of rocuronium
2007-002911-18Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jul 2007
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, single-arm trial of Sugammadex in neuromuscular block (NMB), sponsored by Organon & Co. Primary endpoints: Time to recovery of T4/T1 ratio to 0.9 after sugammadex and Time to manual detection of T4 reappearance. Started Jul 2007; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2007-002911-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002911-18.